Prostate-specific antigen doubling time following radium-223 treatment as a predictor of the clinical course in patients with metastatic castration-resistant prostate cancer
Objectives: To identify useful biomarkers by reviewing laboratory data for a predictor of the clinical course following treatment with radium-223 dichloride (Ra-223) in patients with metastatic castration-resistant prostate cancer. Methods: Eighteen metastatic castration-resistant prostate cancer pa...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-04-01
|
| Series: | SAGE Open Medicine |
| Online Access: | https://doi.org/10.1177/20503121231168493 |
| _version_ | 1827962678415458304 |
|---|---|
| author | Gen Kawaguchi Kohei Akazawa Taro Ikeda Yohei Ikeda Noboru Hara Tsutomu Nishiyama |
| author_facet | Gen Kawaguchi Kohei Akazawa Taro Ikeda Yohei Ikeda Noboru Hara Tsutomu Nishiyama |
| author_sort | Gen Kawaguchi |
| collection | DOAJ |
| description | Objectives: To identify useful biomarkers by reviewing laboratory data for a predictor of the clinical course following treatment with radium-223 dichloride (Ra-223) in patients with metastatic castration-resistant prostate cancer. Methods: Eighteen metastatic castration-resistant prostate cancer patients who were administered Ra-223 at our hospital were retrospectively enrolled in this study. Prostate-specific antigen doubling times before and after the administration of Ra-223 were evaluated as prognostic factors for metastatic castration-resistant prostate cancer patients treated with Ra-223 using the Kaplan–Meier method and Log-rank test. Results: Four patients failed to complete the planned six-time Ra-223 treatments with the exacerbation of their condition. In the 14 patients who completed the planned Ra-223 treatment, before the Ra-223 treatment, no significant differences were observed in overall survival between patients with prostate-specific antigen doubling time of 6 months or less and those with prostate-specific antigen doubling time of more than 6 months or stable ( p = 0.642). Following the completion of the Ra-223 treatment, overall survival was significantly shorter in patients with prostate-specific antigen doubling time of 6 months or less than in those with prostate-specific antigen doubling time of more than 6 months or stable ( p = 0.007). Conclusion: Prostate-specific antigen doubling time after the Ra-223 treatment is a useful predictor of the clinical course following treatment in metastatic castration-resistant prostate cancer patients. |
| first_indexed | 2024-04-09T16:46:45Z |
| format | Article |
| id | doaj.art-4e66c96fd9664fbb938f8d01c8dee677 |
| institution | Directory Open Access Journal |
| issn | 2050-3121 |
| language | English |
| last_indexed | 2024-04-09T16:46:45Z |
| publishDate | 2023-04-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | SAGE Open Medicine |
| spelling | doaj.art-4e66c96fd9664fbb938f8d01c8dee6772023-04-22T11:34:04ZengSAGE PublishingSAGE Open Medicine2050-31212023-04-011110.1177/20503121231168493Prostate-specific antigen doubling time following radium-223 treatment as a predictor of the clinical course in patients with metastatic castration-resistant prostate cancerGen Kawaguchi0Kohei Akazawa1Taro Ikeda2Yohei Ikeda3Noboru Hara4Tsutomu Nishiyama5Department of Radiotherapy, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Minamiuonuma, JapanDepartment of Medical Informatics, Niigata University Medical and Dental Hospital, Niigata, JapanDepartment of Urology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Minamiuonuma, JapanDepartment of Diagnostic Radiology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Minamiuonuma, Niigata, JapanDepartment of Urology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Minamiuonuma, JapanDepartment of Urology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Minamiuonuma, JapanObjectives: To identify useful biomarkers by reviewing laboratory data for a predictor of the clinical course following treatment with radium-223 dichloride (Ra-223) in patients with metastatic castration-resistant prostate cancer. Methods: Eighteen metastatic castration-resistant prostate cancer patients who were administered Ra-223 at our hospital were retrospectively enrolled in this study. Prostate-specific antigen doubling times before and after the administration of Ra-223 were evaluated as prognostic factors for metastatic castration-resistant prostate cancer patients treated with Ra-223 using the Kaplan–Meier method and Log-rank test. Results: Four patients failed to complete the planned six-time Ra-223 treatments with the exacerbation of their condition. In the 14 patients who completed the planned Ra-223 treatment, before the Ra-223 treatment, no significant differences were observed in overall survival between patients with prostate-specific antigen doubling time of 6 months or less and those with prostate-specific antigen doubling time of more than 6 months or stable ( p = 0.642). Following the completion of the Ra-223 treatment, overall survival was significantly shorter in patients with prostate-specific antigen doubling time of 6 months or less than in those with prostate-specific antigen doubling time of more than 6 months or stable ( p = 0.007). Conclusion: Prostate-specific antigen doubling time after the Ra-223 treatment is a useful predictor of the clinical course following treatment in metastatic castration-resistant prostate cancer patients.https://doi.org/10.1177/20503121231168493 |
| spellingShingle | Gen Kawaguchi Kohei Akazawa Taro Ikeda Yohei Ikeda Noboru Hara Tsutomu Nishiyama Prostate-specific antigen doubling time following radium-223 treatment as a predictor of the clinical course in patients with metastatic castration-resistant prostate cancer SAGE Open Medicine |
| title | Prostate-specific antigen doubling time following radium-223 treatment as a predictor of the clinical course in patients with metastatic castration-resistant prostate cancer |
| title_full | Prostate-specific antigen doubling time following radium-223 treatment as a predictor of the clinical course in patients with metastatic castration-resistant prostate cancer |
| title_fullStr | Prostate-specific antigen doubling time following radium-223 treatment as a predictor of the clinical course in patients with metastatic castration-resistant prostate cancer |
| title_full_unstemmed | Prostate-specific antigen doubling time following radium-223 treatment as a predictor of the clinical course in patients with metastatic castration-resistant prostate cancer |
| title_short | Prostate-specific antigen doubling time following radium-223 treatment as a predictor of the clinical course in patients with metastatic castration-resistant prostate cancer |
| title_sort | prostate specific antigen doubling time following radium 223 treatment as a predictor of the clinical course in patients with metastatic castration resistant prostate cancer |
| url | https://doi.org/10.1177/20503121231168493 |
| work_keys_str_mv | AT genkawaguchi prostatespecificantigendoublingtimefollowingradium223treatmentasapredictoroftheclinicalcourseinpatientswithmetastaticcastrationresistantprostatecancer AT koheiakazawa prostatespecificantigendoublingtimefollowingradium223treatmentasapredictoroftheclinicalcourseinpatientswithmetastaticcastrationresistantprostatecancer AT taroikeda prostatespecificantigendoublingtimefollowingradium223treatmentasapredictoroftheclinicalcourseinpatientswithmetastaticcastrationresistantprostatecancer AT yoheiikeda prostatespecificantigendoublingtimefollowingradium223treatmentasapredictoroftheclinicalcourseinpatientswithmetastaticcastrationresistantprostatecancer AT noboruhara prostatespecificantigendoublingtimefollowingradium223treatmentasapredictoroftheclinicalcourseinpatientswithmetastaticcastrationresistantprostatecancer AT tsutomunishiyama prostatespecificantigendoublingtimefollowingradium223treatmentasapredictoroftheclinicalcourseinpatientswithmetastaticcastrationresistantprostatecancer |